---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-039221"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:25:46.760337+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics regains Nasdaq compliance on market value standard; matter closed

## Summary
- Received written confirmation from Nasdaq on Sept 3, 2024 that market value exceeded $35M for 10 consecutive trading days.
- Regains compliance with Nasdaq Listing Rule 5550(b)(2) (Market Value of Listed Securities Standard).
- Previously received notice on May 20, 2024 for non-compliance with Stockholders' Equity Requirement.
- Compliance regained resolves the deficiency; no further Nasdaq action required.

## SEC filing metadata
- accession: 0001628280-24-039221
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024039221/0001628280-24-039221-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024039221/avtx-20240903.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-039221
- JSON: https://secwatch.observer/filing/0001628280-24-039221.json
- Plain text: https://secwatch.observer/filing/0001628280-24-039221.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.